Session	Speakers
Day 1 Conference Opening	Dr. Monika Slovinec D’Angelo, chief research officer, CCRAN
Welcome From CCRAN’s President	Ms. Filomena Servidio-Italiano, president and CEO, CCRAN Ms. Emma Langelier, caregiver to metastatic colorectal cancer patient
Why Timely Access to Molecular Testing Results is an Imperative Healthcare Issue in Canada	Dr. Stephanie Snow, medical oncologist, QEII Health Sciences Centre
Patient Access to Precision Medicines: Molecular Testing and Timely Biomarker Reporting (Patient Group Roundtable)	Overview of barriers: Ms. Filomena Servidio-Italiano, president and CEO, CCRAN GIST: Dr. David Josephy, president, GIST Sarcoma Life Raft Group Canada Breast cancer: Ms. Kimberly Carson, CEO, Breast Cancer Canada Lung cancer: Ms. Michele Wright, patient support initiatives coordinator, Lung Cancer Canada Ovarian cancer: Dr. Alicia Tone, scientific advisor and OvCAN project manager, Ovarian Cancer Canada Melanoma: Ms. Kathleen Barnard, President, Save Your Skin Foundation Pan-Canadian tumor perspective: Ms. Lindsay Timm, community engagement manager, Canadian Cancer Survivor Network Pancreatic cancer: Ms. Stefanie Condon-Oldreive, president and CEO, Craig’s Cause Pancreatic Cancer Society Gastric cancers: Ms. Teresa Tiano, chair and co-founder, My Gut Feeling, Stomach Cancer Foundation of Canada Colorectal cancer: Ms. Filomena Servidio-Italiano president and CEO, CCRAN
Podcast with Lung Cancer Caregiver and Advocate Filomena Servidio-Italiano and Dr. Paul Wheatley-Price About Her Uncle’s Inspiring Journey with Stage IV Disease
Facilitating Access to Precision Therapies for Colorectal Cancer, Lung Cancer, and Thyroid Cancer: Call for Timely Biomarker Reporting	Colorectal cancer perspective: Dr. Sharlene Gill, GI Medical Oncologist, BC Cancer Agency Lung cancer perspective: Dr. Shaqil Kassam, medical oncologist, Southlake Stronach Regional Cancer Centre Thyroid cancer perspective: Dr. Nicole Chau, medical oncologist, BC Cancer Agency Molecular testing perspective: Dr. Brandon Sheffield, pathologist, William Osler Health System
Facilitating Access to Precision Therapies for Breast Cancer, Gastric Cancers, and GIST: Call for Timely Biomarker Reporting	Gastric cancer perspective: Dr. Michael J. Raphael, GI medical oncologist, Odette Cancer Center at Sunnybrook Health Sciences Center Breast cancer perspective: Dr. Christine Brezden-Masley medical oncologist, Mount Sinai Hospital GIST cancer perspective: Dr. Tim Asmis, medical oncologist, The Ottawa Hospital Cancer Centre Molecular testing perspective: Dr. Michael D. Carter, pathologist, Faculty of Medicine, Dalhousie University
Patient Video—Ms. Brenda Clayton, Mother of Young Patient Who Succumbed to Cholangiocarcinoma
Facilitating Access to Targeted Therapies for Melanoma, Gynecologic Cancers, and Pancreatic Cancer: Call for Timely Biomarker Reporting	Gynecologic cancers perspective: Dr. Neesha Dhani, medical oncologist, Princess Margaret Cancer Centre Melanoma perspective: Dr. Eve St-Hilaire, medical oncologist, Dr-Léon-Richard Oncology Centre, Vitalité Health Network Pancreatic cancer perspective: Dr. Patricia Tang, medical oncologist, Tom Baker Cancer Centre Molecular testing perspective: Dr. Aaron Pollett, anatomic pathologist, Division of Diagnostic Medical Genetics, Mount Sinai Hospital
The Forgotten and Rare Cancers: A Call to Action	Rare cancer perspective: Dr. Michael J. Raphael, GI medical oncologist, Odette Cancer Center, Sunnybrook Health Sciences Center Hepatobiliary cancer perspective: Dr. Ravi Ramjeesingh, medical oncologist and associate professor, Nova Scotia Cancer Centre and Dalhousie University, Chair HPB Oncology Halifax Hematology perspective: Dr. Shannon Jackson hematologist, West Coast Hematology, value-based health care physician lead, Providence Health Care, St. Paul’s Hospital Molecular testing perspective: Dr. Brandon Sheffield, pathologist, William Osler Health System
The Role of Liquid Biopsy Measuring Circulating Tumor DNA (ctDNA) in the Management of Cancer	Dr. Stephanie Snow, medical oncologist, QEII Health Sciences Centre Cancer patient perspective: Mr. Rob L., patient with lived colorectal cancer experience who accessed ctDNA testing Clinical ctDNA expert perspective: Dr. Elena Tsvetkova, medical oncologist, London Health Sciences Centre, Local Principal Investigator, COBRA Study Dr. Vincent Funari, Ph.D., chief scientific officer, Imagia Canexia Industry perspective: Dr. Minetta Liu, MD, chief medical officer, Natera Oncology diagnostics laboratory perspective: Dr. Dennis Dobrovolsky, Ph.D., product manager, Oncology, LifeLabs
Day 1 Closing Remarks	Ms. Filomena Servidio-Italiano, OCT, M.A., president and CEO, CCRAN
Conference Day 2 Opening and Welcome	Dr. Monika Slovinec D’Angelo, chief research officer, CCRAN Ms. Filomena Servidio-Italiano, president and CEO, CCRAN
Health System Preparedness for Advanced Biomarker Testing: Implications for Timely Access to Results	Mr. Fred Horne, health policy advisor, former Alberta health minister Mr. Don Husereau, health economist, School of Medicine, University of Ottawa Dr. Harriet Feilotter, molecular geneticist, Department of Pathology and Molecular Medicine, Queens University Dr. Shantanu Banerji, medical oncologist, CancerCare Manitoba Ms. Suzanne Wood, patient with lived colorectal cancer experience whose care was guided by ctDNA
Optimizing Patient Care Pathways Through Timely Access to Biomarker Test Results	Dr. Monika Slovinec D’Angelo, Ph.D., (moderator) VBHC Expert, chief research officer, CCRAN Ms. Natalie Lipschultz, patient with lived colorectal cancer experience Ms. MJ DeCoteau, founder and executive director, Rethink Breast Cancer Dr. Shannon Jackson, hematologist, West Coast Hematology, Value Based Health Care Physician Lead, Department of Hematology, Providence Health Care, St. Paul’s Hospital Dr. Durhane Wong-Rieger, president and CEO, CORD Dr. Samantha Pollard, senior methodologist, Cancer Control Research, BC Cancer Dr. Ju-Yoon Yoon, molecular pathologist, St. Michael’s Hospital, Unity Health Toronto
Patient Video
“My Colorectal Cancer Consultant”—A Novel Online Tool Promoting Patient Engagement and Informed Decision Making about Therapeutic Options	Ms. Filomena Servidio-Italiano, president and CEO, CCRAN Dr. Mary De Vera, epidemiologist, assistant professor, University of British Columbia
Clinician Video—Dr. Christopher Lieu, GI Medical Oncologist, University of Colorado Hospital
The Utility and Value of Comprehensive Genomic Profiling (CGP) in Cancer Care	Cancer patient perspective: Mr. Allen Chankowsky, rare-cancer patient with lived experience U.S. CGP research and program perspective: Dr. Razelle Kurzrock, professor of medicine, associate director of clinical research; Linda T. and John A. Mellowes, chair of precision oncology, MCW Cancer Center and Center for Genomic Sciences and Precision Medicine; founding director, Michels Rare Cancers Research Laboratories, Froedtert and MCW Canadian CGP research and program perspective: Dr. Howard Lim, medical oncologist, B.C. Cancer Agency Value-based healthcare perspective: Ms. Eva Villalba, MBA VBHC Expert, executive director, Quebec Cancer Coalition
What Will it Take to Adopt Comprehensive Genomic Profiling (CGP) as a Standard of Cancer Care in Canada?	Mr. Don Husereau, health economist, School of Medicine, University of Ottawa Patient perspective: Dr. Marko Yurkovich, primary care physician and stage IV colorectal cancer 4 patient Clinical practice perspective on CGP in cancer care: Dr. Cathy Eng, medical oncologist and professor, Vanderbilt-Ingram Cancer Center, Nashville, TN, U.S. CGP access perspective (Canada): Dr. Faisal M. Khan PhD, D(ABHI), director, Molecular Diagnostics, OncoHelix NGS technology perspective: Dr. Jeffrey M. Smith, NGS precision medicine director, Clinical Next-Generation Sequencing and Oncology Division, Thermo Fisher Scientific CGP access perspective (U.S.): Dr. John L. Fox, MD MHA senior medical director for the Americas, Market Access, Illumina
Closing Remarks	Ms. Filomena Servidio-Italiano, OCT, M.A. president and CEO, CCRAN
Time Session Title	Speakers
Conference Day 2 Opening and Welcome	Dr. Monika Slovinec D’Angelo, chief research officer, CCRAN Ms. Filomena Servidio-Italiano, president and CEO, CCRAN
Health System Preparedness for Advanced Biomarker Testing: Implications for Timely Access to Results	Mr. Fred Horne, health policy advisor, former Alberta health minister Mr. Don Husereau, health economist, School of Medicine, University of Ottawa Dr. Harriet Feilotter, molecular geneticist, Department of Pathology and Molecular Medicine, Queens University Dr. Shantanu Banerji, medical oncologist, CancerCare Manitoba Ms. Suzanne Wood, patient with lived colorectal cancer experience whose care was guided by ctDNA
Optimizing Patient Care Pathways Through Timely Access to Biomarker Test Results	Dr. Monika Slovinec D’Angelo, Ph.D., (Moderator) VBHC Expert, chief research officer, CCRAN Ms. Natalie Lipschultz, patient with lived colorectal cancer experience Ms. MJ DeCoteau, founder and executive director, Rethink Breast Cancer Dr. Shannon Jackson, hematologist, West Coast Hematology, Value Based Health Care Physician Lead, Department of Hematology, Providence Health Care, St. Paul’s Hospital Dr. Durhane Wong-Rieger, president and CEO, CORD Dr. Samantha Pollard, senior methodologist, Cancer Control Research, BC Cancer Dr. Ju-Yoon Yoon, molecular pathologist, St. Michael’s Hospital, Unity Health Toronto
Patient Video
“My Colorectal Cancer Consultant”—A Novel Online Tool Promoting Patient Engagement and Informed Decision Making about Therapeutic Options	Ms. Filomena Servidio-Italiano, president and CEO, CCRAN Dr. Mary De Vera, epidemiologist, assistant professor, University of British Columbia
Clinician Video—Dr. Christopher Lieu, GI Medical Oncologist, University of Colorado Hospital
The Utility and Value of Comprehensive Genomic Profiling (CGP) in Cancer Care	Cancer patient perspective: Mr. Allen Chankowsky, rare-cancer patient with lived experience U.S. CGP research and program perspective: Dr. Razelle Kurzrock, professor of medicine, associate director of clinical research; Linda T. and John A. Mellowes, chair of precision oncology, MCW Cancer Center and Center for Genomic Sciences and Precision Medicine; founding director, Michels Rare Cancers Research Laboratories, Froedtert and MCW Canadian CGP research and program perspective: Dr. Howard Lim, medical oncologist, B.C. Cancer Agency Value-based healthcare perspective: Ms. Eva Villalba, MBA, VBHC expert, executive director, Quebec Cancer Coalition
What Will it Take to Adopt Comprehensive Genomic Profiling (CGP) as a Standard of Cancer Care in Canada?	Mr. Don Husereau, health economist, School of Medicine, University of Ottawa Patient perspective: Dr. Marko Yurkovich, primary care physician and stage IV colorectal cancer 4 patient Clinical practice perspective on CGP in cancer care: Dr. Cathy Eng, medical oncologist and professor, Vanderbilt-Ingram Cancer Center, Nashville, TN, U.S. CGP access perspective (Canada): Dr. Faisal M. Khan PhD, D(ABHI), director, Molecular Diagnostics, OncoHelix NGS technology perspective: Dr. Jeffrey M. Smith, NGS precision medicine director, Clinical Next-Generation Sequencing and Oncology, Division, Thermo Fisher Scientific CGP access perspective (U.S.): Dr. John L. Fox, MD MHA senior medical director for the Americas, Market Access, Illumina
Closing Remarks	Ms. Filomena Servidio-Italiano, OCT, M.A. president and CEO, CCRAN